Back to News
Market Impact: 0.15

Lundbeck to highlight mechanistic insights on bexicaserin's dual mode of action at the European Epilepsy Congress

Source: PR Newswire

Healthcare & BiotechTechnology & InnovationCompany Fundamentals

Preclinical data suggest bexicaserin has a dual mode of action—reducing excitatory neuronal activity while increasing inhibitory activity—indicating broader antiseizure potential. The findings span focal, generalized motor, and absence seizure models across different conditions, though they are limited to preclinical evidence.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

mildly positive

Sentiment Score

0.20

More News